Approved for use through 05/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/576,733-Conf. #4494	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	April 21, 2006	
l s	TATEMENT B	3Y /	APPLICANT	First Named Inventor	Ian Taylor	
				Art Unit	1643	
(Use as many sheets as necessary)				Examiner Name	K. A. Canella	
Sheet	1	of	2	Attorney Docket Number	5181 [67859(303981)]	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear			
	AA*	US-20030190689	10-09-2003	Crosby et al.				

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear			

Examiner	Date	
Signature	Considered	

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted via the Office electronic filing system in accordance with § 1.6(a)(4).

Dated: May 7, 2009 Electronic Signature for Gabriel J. McCool: /Gabriel J. McCool/

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (04-09)

Approved for use through 05/31/2009. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	bstitute for form 1449/PTO	,		Complete if Known		
				Application Number	10/576,733-Conf. #4494	
11	NFORMATION	1 DI	SCLOSURE	Filing Date	April 21, 2006	
S	STATEMENT E	3Y /		First Named Inventor	lan Taylor	
				Art Unit	1643	
(Use as many sheets as necessary)			; necessary)	Examiner Name	K. A. Canella	
Sheet	2	of	2	Attorney Docket Number 5181 [67859(303981)]		

NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of						
Examiner Initials	Cite No.1	the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²			
	CA	S. S. W. Ng, et al.: "Effects of the Epidermal Growth Factor Receptor Inhibitor OSI-774, Tarceva, on Downstream Signaling Pathways and Apoptosis in Human Pancreatic Adenocardinoma," Molecular Cancer Therapeutics, Vol. 1, No. 18, August 2002, pgs. 777-783.				
	СВ	M. R. Ricciardi et al.: "Flow Cytometric Monitoring of Constitutive MAPK Phosphorylation and of Pharmacodynamic MEK/MAPK Inhibition in Primary AML Samples," The American Society of Hematology, Vol. 100, No. 11, Abstract No. 4610, December, 2002, pg. 270b				
	CC	J. A. Aguirre-Ghiso, et al.: "ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK," Cancer Research, Vol. 63, No. 7, April, 2003, pgs. 1684-1695.				
	CD	J-H Zhu, et al.: "Cytoplasmic Aggregates of Phosphorylated Extracellular Signal-Regulated Protein Kinases in Lewy Body Diseases," American Journal of Pathology, Vol. 161, No. 6, December, 2002, pgs. 2087-2098.				
	CE	K. Jorgensen et al.: "Expression of Activated Extracellular Signal-Regulated Kinases 1/2 in Malignant Melanomas: Relationship with Clinical Outcome," Clinical Cancer Research, Vol. 9, November, 2003, pgs. 5325-5331.				
	CF	S. Tanimura et al.: "Specific Blockade of the ERK Pathway Inhibits the Invasiveness of Tumor Cells: Down-Regulation of Matrix Metalloproteinase-3/-9/-14 and CD44," Biochemical and Biophysical Research Communications, Vol. 304, 2003, pgs. 801-806.				
	CG	A. Adeyinka et al.: "Activated Mitogen-activated Protein Kinase Expression During Human Breast Tumorigenesis and Breast Cancer Progression," Clinical Cancer Research, Vol. 8, June, 2002, pgs. 1747-1753.				
	СН	Z. Fu et al.: "Effects of Raf Kinase Inhibitor Protein Expression on Suppression of Prostate Cancer Metastasis," Journal of the National Cancer Institute, Vol. 95, No. 12, June 18, 2003, pgs. 878-889.				

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.